Aperia Technologies Introduces Virtual Training Infrastructure, Enhances Fleet Support Amidst Global Pandemic

Nvidia gets China's go-ahead for $6.9 billion Mellanox deal

Mellanox shares rose nearly 2% in afternoon trading, while Nvidia jumped about 4%. Many acquisitions between U.S. and international companies with significant operations in China have faced challenges in securing approval from the country's regulator due to a bitter trade war between the two largest economies of the world that started in January, 2018. Two years ago, U.S. chipmaker Qualcomm Inc had to walk away from a $44 billion deal to buy NXP Semiconductors after failing to secure Chinese regulatory approval....

Moderna’s COVID-19 Vaccine Potential Taking Shape

COVID-19 has put the world in a chokehold, but one biotech name appears to be well on its way to delivering a match-winning knockout.On Tuesday, Moderna (MRNA) hosted a virtual vaccines day in which management as well as infectious disease (ID) key opinion leaders (KOLs) highlighted scientific, regulatory and commercial considerations related to Moderna's vaccine programs, including its experimental vaccine against COVID-19, mRNA-1273. With respect to this candidate, Moderna expects to have initial Phase 1 immunogenicity data in the summer, and then to progress quickly into Phase 2. After a dose has been selected, Phase 2b/3 studies are slated to kick off in the fall.Weighing in for Chardan Capital, analyst Geulah Livshits cites several takeaways from the discussion that played into her bullish thesis. There are advantages to using an mRNA approach including ease of design, natural antigen expression, triggering of both B and T cell responses, activity at lower doses...